Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 162fludarabine phosphate 127Mycophenolic Acid 96Tacrolimus 92Whole-Body Irradiation 85Busulfan 85Peripheral Blood Stem Cell Transplantation 82fludarabine 79Cyclosporine 68Melphalan 63Antilymphocyte Serum 58Filgrastim 56Methotrexate 55Thiotepa 39Radiotherapy 39Cord Blood Stem Cell Transplantation 34Granulocyte Colony-Stimulating Factor 29Cytarabine 28Methylprednisolone 27Stem Cell Transplantation 26Sirolimus 24thymoglobulin 23Etoposide 23Clofarabine 22Rituximab 19Flow Cytometry 15Cyclosporins 15sargramostim 13Specimen Handling 13Alemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × lorvotuzumab mertansine × Myeloid × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡